Novo Holdings A/S - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 84 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
Novo Holdings A/S ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$32,714,000
+65.0%
1,100,0000.0%2.42%
+57.8%
Q2 2023$19,822,000
+12.2%
1,100,0000.0%1.53%
+31.4%
Q1 2023$17,666,000
+31.0%
1,100,000
+49.2%
1.17%
+38.5%
Q4 2022$13,488,143
+8.7%
737,057
+16.7%
0.84%
+42.5%
Q3 2022$12,405,000
+5.3%
631,6270.0%0.59%
+1.9%
Q2 2022$11,780,000
+26.3%
631,627
+48.7%
0.58%
+17.9%
Q1 2022$9,326,000
+124.9%
424,897
+56.6%
0.49%
+187.7%
Q1 2021$4,147,000
+8.3%
271,3780.0%0.17%
+4.3%
Q4 2020$3,829,000
-9.9%
271,3780.0%0.16%
-22.3%
Q3 2020$4,252,000
+13.2%
271,378
+26.5%
0.21%
-13.2%
Q2 2020$3,757,000
+55.4%
214,453
+30.4%
0.24%
+50.9%
Q1 2020$2,417,000
-28.6%
164,453
+21.8%
0.16%
-26.1%
Q4 2019$3,387,000
+66.8%
135,0090.0%0.22%
-37.4%
Q3 2019$2,031,000
-39.8%
135,0090.0%0.35%
-26.4%
Q2 2019$3,375,000
+9.8%
135,0090.0%0.47%
+4.0%
Q1 2019$3,073,000
-24.1%
135,0090.0%0.46%
-20.2%
Q4 2018$4,049,000
-5.8%
135,009
-10.0%
0.57%
+67.2%
Q3 2018$4,298,000150,0000.34%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2021
NameSharesValueWeighting ↓
Saturn V Capital Management LP 623,819$11,336,5019.41%
Finepoint Capital LP 822,745$15,0564.87%
Bain Capital Life Sciences Investors, LLC 2,305,558$42,1924.72%
Opaleye Management Inc. 732,000$13,395,6004.66%
5AM Venture Management, LLC 862,286$15,779,8344.24%
SPHERA FUNDS MANAGEMENT LTD. 671,644$12,291,0852.64%
First Light Asset Management, LLC 1,329,313$24,326,4282.26%
BRAIDWELL LP 3,469,674$63,495,0342.13%
BVF INC/IL 2,736,613$50,080,0182.11%
Perceptive Advisors 4,039,276$73,918,7512.08%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders